Research Reveals Persistent Drug Pricing Distortions from PBM-Owned Pharmaceutical Companies

More recently, fellow drug channel archaeologist Adam Fein recently also wondered what PBM-owned drug companies list price behavior might tell us about the incentives within the U.S. drug pricing system.

A newly published paper from researchers Michael Carrier and Rachel Sachs further explores the competitive concerns and seeming misalignment of PBM incentives.

This summer, we launched a new research work that examined the costs yielded by a reborn and evolved species of the prescription drug supply chain: drug companies who are also part of larger vertically integrated pharmacy benefit manager (PBM) corporations.

In essence, PBMs are intended to be a st...

So while our study from this summer dug into the publicly-available data that shows the output of the costs reported in the Medicaid, Medicare